The estimated Net Worth of Jacqueline Northcut is at least $2.4 Tausend dollars as of 5 May 2017. Ms Northcut owns over 1,000 units of Moleculin Biotech Inc stock worth over $2,400 and over the last 8 years she sold MBRX stock worth over $0.
Sign up
Ms Northcut MBRX stock SEC Form 4 insiders trading
Ms has made over 1 trades of the Moleculin Biotech Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she bought 1,000 units of MBRX stock worth $820 on 5 May 2017.
The largest trade she's ever made was buying 1,000 units of Moleculin Biotech Inc stock on 5 May 2017 worth over $820. On average, Ms trades about 500 units every 0 days since 2016. As of 5 May 2017 she still owns at least 1,000 units of Moleculin Biotech Inc stock.
You can see the complete history of Ms Northcut stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Jacqueline Northcut biography
Jacqueline Northcut is the Consultant at Moleculin Biotech Inc.
How old is Ms Northcut?
Ms Northcut is 59, she's been the Consultant of Moleculin Biotech Inc since . There are 8 older and 2 younger executives at Moleculin Biotech Inc. The oldest executive at Moleculin Biotech Inc is Dr. Donald H. Picker Ph.D., 75, who is the Chief Scientific Officer.
What's Ms Northcut's mailing address?
Jacqueline's mailing address filed with the SEC is C/O MOLECULIN BIOTECH, INC., 2575 WEST BELLFORT, SUITE 333, HOUSTON, TX, 77054.
Insiders trading at Moleculin Biotech Inc
Over the last 8 years, insiders at Moleculin Biotech Inc have traded over $340,000 worth of Moleculin Biotech Inc stock and bought 433,338 units worth $371,310 . The most active insiders traders include Walter V Klemp, John M Climaco und Waldemar Priebe. On average, Moleculin Biotech Inc executives and independent directors trade stock every 75 days with the average trade being worth of $69,293. The most recent stock trade was executed by Walter V Klemp on 2 July 2024, trading 982 units of MBRX stock currently worth $2,357.
What does Moleculin Biotech Inc do?
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.
What does Moleculin Biotech Inc's logo look like?
Complete history of Ms Northcut stock trades at Moleculin Biotech Inc
Moleculin Biotech Inc executives and stock owners
Moleculin Biotech Inc executives and other stock owners filed with the SEC include:
-
Walter V. Klemp,
Founder, Chairman, Pres & CEO -
Jonathan P. Foster CPA,
Exec. VP & CFO -
Jonathan P. Foster,
Exec. VP & CFO -
Dr. Donald H. Picker Ph.D.,
Chief Scientific Officer -
Dr. Donald H. Picker,
Chief Scientific Officer -
Dr. Sandra L. Silberman M.D., Ph.D.,
Chief Medical Officer of New Products -
Dr. John Paul Waymack M.D., Sc.D.,
Sr. Chief Medical Officer -
Louis Ploth Jr.,
Independent Advisor -
Jacqueline Northcut,
Consultant -
Dr. Sandra L. Silberman,
Chief Medical Officer of New Products -
Dr. Robert C. Shepard FACP, M.D., F.A.C.P.,
Chief Medical Officer of Annamycin -
Dr. Waldemar Priebe Ph.D.,
Co-Founder & Chairman of Scientific Advisory Board -
Jacqueline Northcut,
Director -
Michael D Cannon,
Director -
Robert E. George,
Director -
John M Climaco,
Director -
Waldemar Priebe,
10% owner -
Donald H Picker,
Chief Science Officer -
Walter V Klemp,
CEO and President -
Elizabeth Cermak,
Director -
Joy Yan,
Director -
Jonathan P. Foster,
Chief Financial Officer